Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [68Ga]GA-DOTA-TATE, [68Ga]Ga-DOTA-TATE
Ga-DOTA-TATE · 1 trial · 1 indication
Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). * TP participants were those who showed at least one lesion based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FN participants were those who did not show any lesions based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but showed at least one lesion based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]
Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). * TN participants were those who did not show any lesions based on both \[68Ga\]Ga-DOTA-TATE PET/CT imaging and CIM by central read. * FP participants were those who showed at least one lesion based on \[68Ga\]Ga-DOTA-TATE PET/CT imaging but did not show any lesions based on CIM by central read. True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\]
Subject-level sensitivity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging positive participants (i.e. TP participants) among CIM positive participants (i.e. TP or FN participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Sensitivity = TP / (TP + FN)
Subject-level specificity is defined as the proportion of \[68Ga\]Ga-DOTA-TATE PET/CT imaging negative participants (i.e. TN participants) among CIM negative participants (i.e. TN or FP participants). True Positive \[TP\] False Positive \[FP\] False Negative \[FN\] True Negative \[TN\] Specificity = TN / (TN + FP).
| Arm | Type | Description |
|---|---|---|
| [68Ga]Ga-DOTA-TATE | EXPERIMENTAL | All eligible participants will receive \[68Ga\]Ga-DOTA-TATE via intravenous injection at a dose of 2 MBq/kg (0.054 mCi/kg) of body weight up to a maximum total dose of 200 MBq (5.4 mCi) |
| Name | Type | Description |
|---|---|---|
| [68Ga]Ga-DOTA-TATE | DRUG | Single intravenous injection of \[68Ga\]Ga-DOTA-TATE determined by body weight (2 Mega-Becquerel (MBq) / kilogram (kg) (0.054 Millicurie (mCi)/kilogram (kg)) of body weight up to a maximum total dose of 200 MBq (5.4 mCi)) at the imaging day (Day 1). |
| 68Ge/68Ga Generator | DRUG | Radionuclide generator |
Key Inclusion Criteria: 1. Signed informed consent must have been obtained prior to participation in the study 2. Participants must have been adults \>= 18 years of age 3. ECOG performance status 0-2 4. For patient with NENs only: Participants were to be confirmed NENs based on histopathology, imag...
Ga-DOTA-TATE is a small molecule being developed for use in neuroendocrine neoplasms (NENs). It is an investigational diagnostic agent studied in a Phase 3 clinical trial in Japan, which included patients with neuroendocrine neoplasms and healthy volunteers.
Ga-DOTA-TATE is a radiolabeled somatostatin analog that binds to somatostatin receptors, which are often overexpressed on neuroendocrine tumor cells. This allows for imaging and detection of neuroendocrine neoplasms.
Ga-DOTA-TATE is being developed by Novartis AG, which is publicly traded under the ticker symbol NVS.
Ga-DOTA-TATE is in Phase 3 clinical development. It is an investigational agent and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
Ga-DOTA-TATE has one completed Phase 3 trial, NCT06240741, titled 'A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan.' The trial enrolled 71 participants and was conducted in Japan.
Yes, Ga-DOTA-TATE is also known as [68Ga]Ga-DOTA-TATE and [68Ga]Ga-DOTA-TATE. These names refer to the same investigational compound.